{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:55:22Z","timestamp":1791474922564,"version":"4.3.4"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Direct acting oral anticoagulants (DOACs) are widely utilized in the management of venous thromboembolism. Numerous studies have demonstrated that their safety and efficacy surpass those of warfarin. Nevertheless, the evidence supporting their use in treating venous thrombosis among patients with morbid obesity remains inadequate, necessitating further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive computer search was performed for studies on direct acting oral anticoagulants for venous thrombosis in patients with morbid obesity, published in the Cochrane Library, PubMed, and Embase databases prior to June 20, 2026. The quality of the literature was assessed using the Cochrane risk-of-bias tool and the Newcastle\u2013Ottawa Scale. Meta-analysis was conducted utilizing RevMan 5.3 software, focusing on recurrent thromboembolic events, any bleeding event, and major bleeding events as outcome metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 1251 studies were retrieved, with 20 ultimately included, encompassing 44,672 morbidly obese VTE patients. Among them, 18,433 were in the direct acting oral anticoagulants group, and 26,239 were in the warfarin group. The results of the meta-analysis indicate that direct acting oral anticoagulants may have a lower risk of thrombosis recurrence (OR\u2005=\u20050.74, 95% confidence interval [CI]: 0.59\u20130.92,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.01) and total bleeding (OR\u2005=\u20050.72, 95% CI: 0.66\u20130.77) compared to warfarin. The risk of major bleeding (OR\u2005=\u20050.69, 95% CI: 0.60\u20130.80,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.01) with direct acting oral anticoagulants may be lower than that with warfarin. Subgroup analysis indicated that standard doses of DOACs were more effective than warfarin in managing VTE in patients with morbid obesity, while maintaining comparable safety levels. Dosage adjustments may not be necessary. In the treatment of morbidly obese patients with venous thromboembolism, rivaroxaban demonstrates a thrombosis recurrence risk similar to warfarin but a lower risk of major bleeding. Similarly, the use of apixaban in this patient population shows reduced risks of both thrombosis recurrence and major bleeding compared to warfarin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The safety and efficacy of direct acting oral anticoagulants in the treatment of venous thromboembolism in patients with morbid obesity may be superior to warfarin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050355","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:06:29Z","timestamp":1787331989000},"page":"e50355","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of direct acting oral anticoagulants in the treatment of patients with morbid obesity with venous thromboembolism"],"prefix":"10.1097","volume":"105","author":[{"given":"Jinping","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Xi\u2019an International Medical Center Hospital, Xi\u2019an, Shaanxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xi\u2019an International Medical Center Hospital, Xi\u2019an, Shaanxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-0839","authenticated-orcid":false,"given":"Yajuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xi\u2019an International Medical Center Hospital, Xi\u2019an, Shaanxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xi\u2019an International Medical Center Hospital, Xi\u2019an, Shaanxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xi\u2019an International Medical Center Hospital, Xi\u2019an, Shaanxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.3390\/jcm15124430","article-title":"Update on obesity and its relationship to atherosclerotic cardiovascular disease and associated risk factors.","volume":"15","author":"Ahmad","year":"2026","journal-title":"J Clin Med"},{"key":"R2-20260917","first-page":"661","article-title":"Epidemiology and trend of obesity in the world and China [in Chinese].","volume":"32","author":"Bing","year":"2025","journal-title":"Chin J Basic Clin General Surg"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2213-8587(21)00118-2","article-title":"Health policy and public health implications of obesity in China.","volume":"9","author":"Wang","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1024\/0301-1526\/a001145","article-title":"Epidemiology of deep vein thrombosis.","volume":"53","author":"Wolf","year":"2024","journal-title":"Vasa"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"131","DOI":"10.17476\/jmbs.2025.14.2.131","article-title":"Obesity and venous thromboembolism: mechanisms, clinical implications, and prevention strategies with a focus on bariatric surgery.","volume":"14","author":"Jung","year":"2025","journal-title":"J Metab Bariatr Surg"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.numecd.2021.07.018","article-title":"Association between body mass index, waist circumference, and relative fat mass with the risk of first unprovoked venous thromboembolism.","volume":"31","author":"Caiano","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2020.05.014","article-title":"Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: a systematic review and dose-response meta-analysis of cohort studies among four million participants.","volume":"192","author":"Rahmani","year":"2020","journal-title":"Thromb Res"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11239-020-02361-8","article-title":"Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design.","volume":"52","author":"Cardinal","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation.","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"e35015","DOI":"10.1097\/MD.0000000000035015","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous thromboembolism: a meta-analysis.","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine (baltim)"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/0115701611330090250130075810","article-title":"Comparative efficacy and safety of direct oral anticoagulants and warfarin in morbidly obese Patients (BMI \\>40\u2009kg\/m2): a systematic review and meta-analysis.","volume":"23","author":"Sagris","year":"2025","journal-title":"Curr Vasc Pharmacol"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R15-20260917","first-page":"e238260","article-title":"Safety and efficacy of direct oral anticoagulants vs warfarin in patients with obesity and venous thromboembolism: a retrospective analysis.","volume":"51","author":"Tu","year":"2024","journal-title":"Tex Heart Inst J"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/10600280231212186","article-title":"Direct oral anticoagulants: probability of recurrent venous thromboembolism and bleeding risk in an obese population.","volume":"58","author":"Pilkerton","year":"2024","journal-title":"Ann Pharmacother"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.jtha.2024.08.009","article-title":"Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients.","volume":"22","author":"Dobry","year":"2024","journal-title":"J Thromb Haemost"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11239-023-02774-1","article-title":"DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network.","volume":"55","author":"Martin","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/87551225231196748","article-title":"Direct oral anticoagulants for the treatment of venous thromboembolism in obesity.","volume":"39","author":"Hattaway","year":"2023","journal-title":"J Pharm Technol"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/10600280221089008","article-title":"Management of venous thromboembolism in morbid obesity with rivaroxaban or warfarin.","volume":"56","author":"Weaver","year":"2022","journal-title":"Ann Pharmacother"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jha2.418","article-title":"Comparing direct oral anticoagulants and vitamin K antagonist use in morbidly obese patients with venous thromboembolism: a single center retrospective cohort study.","volume":"3","author":"Scott","year":"2022","journal-title":"EJHaem"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/phar.2655","article-title":"Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.","volume":"42","author":"Crouch","year":"2022","journal-title":"Pharmacotherapy"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"e008005","DOI":"10.1161\/CIRCOUTCOMES.121.008005","article-title":"Anticoagulation treatment and outcomes of venous thromboembolism by weight and Body Mass Index: insights from the veterans health administration.","volume":"14","author":"Perino","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11239-020-02199-0","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.","volume":"51","author":"Costa","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s12325-021-01716-8","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY.","volume":"38","author":"Cohen","year":"2021","journal-title":"Adv Ther"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/jcm10020200","article-title":"Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity.","volume":"10","author":"Cohen","year":"2021","journal-title":"J Clin Med"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.thromres.2020.04.015","article-title":"A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population.","volume":"192","author":"Patil","year":"2020","journal-title":"Thromb Res"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1060028019886092","article-title":"Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight.","volume":"54","author":"Perales","year":"2020","journal-title":"Ann Pharmacother"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.thromres.2020.01.011","article-title":"Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism.","volume":"187","author":"Quan","year":"2020","journal-title":"Thromb Res"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ejh.13471","article-title":"Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight.","volume":"105","author":"Wysokinski","year":"2020","journal-title":"Eur J Haematol"},{"key":"R31-20260917","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.thromres.2019.08.021","article-title":"Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs.","volume":"182","author":"Spyropoulos","year":"2019","journal-title":"Thromb Res"},{"issue":"Supple1","key":"R32-20260917","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1182\/blood-2019-121765","article-title":"Efficacy and safety of direct oral anticoagulants in obese patients with venous thromboembolism.","volume":"134","author":"Sa","year":"2019","journal-title":"Blood"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","article-title":"Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.","volume":"6","author":"Kushnir","year":"2019","journal-title":"Lancet Haematol"},{"key":"R34-20260917","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies.","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"R35-20260917","doi-asserted-by":"crossref","first-page":"1457280","DOI":"10.3389\/fphar.2024.1457280","article-title":"Anticoagulation approach in morbid obesity: a comprehensive review on venous thromboembolism management.","volume":"15","author":"Sorodoc","year":"2024","journal-title":"Front Pharmacol"},{"key":"R36-20260917","first-page":"320","article-title":"Safety and efficacy of direct oral anticoagulants compared to warfarin in patients with venous thromboembolism and morbid obesity.","volume":"19","author":"Katel","year":"2025","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"R37-20260917","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11239-024-02955-6","article-title":"Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity.","volume":"57","author":"Sperry","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"R38-20260917","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/rth2.12146","article-title":"Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study.","volume":"2","author":"Piran","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"R39-20260917","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"Supple 1","key":"R40-20260917","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1182\/blood-2024-203985","article-title":"The effect of bariatric surgery on rivaroxaban plasma concentration; long-term follow-up study.","volume":"144","author":"Alqahtani","year":"2024","journal-title":"Blood"},{"key":"R41-20260917","first-page":"10600280221077158","article-title":"Observed apixaban anti-xa levels in obese patients.","author":"Harkness","year":"2022","journal-title":"Ann Pharmacother"},{"key":"R42-20260917","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0040-1715834","article-title":"Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study.","volume":"121","author":"Martin","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:01:37Z","timestamp":1789624897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050355"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":42,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050355","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2026-07-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}